SENS-401 (R-Azasetron Besylate)
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hearing Loss Ototoxic
Conditions
Hearing Loss Ototoxic
Trial Timeline
Dec 30, 2022 → Jun 11, 2025
NCT ID
NCT05628233About SENS-401 (R-Azasetron Besylate)
SENS-401 (R-Azasetron Besylate) is a phase 2 stage product being developed by Sensorion for Hearing Loss Ototoxic. The current trial status is completed. This product is registered under clinical trial identifier NCT05628233. Target conditions include Hearing Loss Ototoxic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05628233 | Phase 2 | Completed |
| NCT05258773 | Phase 2 | Completed |
Competing Products
6 competing products in Hearing Loss Ototoxic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGF166 | Novartis | Phase 1/2 | 41 |
| Rilonacept | Regeneron Pharmaceuticals | Phase 1 | 32 |
| PF-04958242 + PF-04958242 + Placebo | Biogen | Phase 1 | 30 |
| PIPE-505 + Placebo | Contineum Therapeutics | Phase 1/2 | 33 |
| SENS-401 (R-Azasetron Besylate) | Sensorion | Phase 2 | 44 |
| SENS-401 + SENS-401 | Sensorion | Phase 2/3 | 57 |